Introduction
> Bendamustine is a novel alkylating agent with a benzimidazole ring that inhibits tumor cell growth by inducing mitotic failure and apoptosis. > In March 2008, bendamustine was approved for the treatment of chronic lymphocytic leukemia in the United States. > A previously published Phase II study demonstrated that single-agent bendamustine produced durable objective responses in patients with recurrent, rituximab-refractory, indolent B-cell lymphoma (JCO 2008; 26:204) . > Current study objective:
Overall Response Rate (ORR) and Median Duration of Response (DoR) NA = not available * ORR was assessed by independent review committee. ORR was defined as proportion of patients with best response ≥ partial response. Kahl BS et al. Cancer 2010; 116(1) :106-14. Adverse Events* (N = 100) Kahl BS et al. Cancer 2010; 116( Neutropenia 38%
* Six possible treatment-related deaths occurred on study.
Conclusions
> Single-agent bendamustine produced a high rate of response in patients with recurrent, indolent NHL.
-ORR: 75% for overall patient group -DoR: 9.2 mos for overall patient group -Median progression-free survival: 9.3 mos for overall patient group (data not shown)
> The toxicity profile of bendamustine was acceptable.
-Major toxicities associated with treatment were reversible myelosuppression, gastrointestinal toxicity and infection.
> These data support the clinical benefit of bendamustine in patients with indolent B-cell NHL that is refractory to rituximab.
Kahl BS et al. Cancer 2010; 116(1):106-14. Faculty Comments DR FOSS: This is an important paper as it demonstrated a high overall response rate and a median response duration and progression-free survival of approximately nine months for patients with disease that was refractory to other therapies, including rituximab. The toxicity was relatively mild, and patients tolerated the therapy well. It gives us another option for patients with low-grade lymphomas who will receive multiple lines of therapy during the course of their disease.
DR VOSE:
The study used a bendamustine dose of 120 mg/m 2 on days 1 and 2 every three weeks. I would say that most people nowadays use the 90-mg/m 2 days 1 and 2 dose to start with, and that is better tolerated.
Introduction
> Bendamustine is approved as a single-agent treatment for relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). > A Phase II trial of bendamustine and rituximab (BR) showed high activity in relapsed indolent lymphomas that was accompanied by low toxicity (JCO 2005; 23:3383 
Summary and Conclusions
> BR significantly improved CR and PFS compared to CHOP-R in patients with indolent and mantle-cell lymphoma.
-CR: 39.6% vs 30.0% -PFS: 54.9 mos vs 34.8 mos > Overall survival did not differ between the two study arms (data not shown). > The tolerability profile with BR was better compared to CHOP-R. Faculty Comments DR FISHER: This paper was impressive in its results, and it evaluated BR compared to R-CHOP in all kinds of indolent lymphomas, particularly follicular lymphoma (FL) and mantle-cell lymphoma (MCL). Though we have not seen publication yet, BR produced a better PFS and CR rate with less toxicity. BR also appears to work better preferentially in FL and MCL. When the toxicity of CHOP is prohibitive, BR is a reasonable option, and with additional analysis it may emerge as a treatment with value to all patients.
DR FOSS:
This is a key study for the initial management of lowgrade lymphomas, and based on the efficacy and tolerability data, BR is an option for first-line therapy for patients with lowgrade lymphomas who require cytotoxic chemotherapy. 
Conclusions
> R maintenance therapy for two years significantly improved PFS for pts with previously untreated FL who responded to induction with R-chemotherapy. > Benefits of R maintenance were seen in all major subgroups (data not shown). > These data provide evidence of an incremental benefit with R maintenance following initial R-chemotherapy for patients with FL. > Data from the ongoing ECOG-E4402 (RESORT) trial will address how R maintenance compares to re-treatment with R at disease progression. Faculty Comments DR FISHER: This is a landmark study and confirms the role of maintenance rituximab in patients with FL treated with rituximab/chemotherapy as initial therapy. The study shows convincingly that two years of rituximab maintenance adds to failure-free-survival, progression-free-survival and time to treatment failure. The benefit was in all patient subgroups, and in my view it is indicated for all of these patients and should be used in a uniform fashion. Most people agree with me, though some believe that we should wait for a survival benefit.
DR FOSS:
This is a long-awaited paper and is quite important as it demonstrates the benefit of rituximab maintenance even after receiving a rituximab-based induction regimen. 
Faculty Comments
DR FOSS: R maintenance in the setting of relapsed/refractory FL was shown to have improved clinical outcome compared to observation. These long-term data reconfirm the benefit on PFS with R maintenance in this setting. The study is important in providing insight on how to care for patients with low-grade lymphoma who achieve remission in the relapsed setting.
DR FISHER:
This study asked the question of clinical benefit with R maintenance for relapsed/refractory FL. The benefit is clear in terms of PFS, for which -even in the relapsed/refractory setting -R maintenance is valuable and works effectively, and the difference in five-year survival is reported as 74 percent with R maintenance and 64 percent with observation, although it is not statistically superior with a p-value of 0.07.
Introduction
> The introduction of rituximab (R) has led to improved survival for patients with follicular lymphoma (FL). > Despite improved survival with R, relapse is inevitable and new treatment algorithms are needed. > VBR was generally well tolerated in this patient population, which included patients with heavily pretreated (46% ≥3 prior lines of therapy) and high-risk FL (data not shown). > The response rates were improved in patients treated with VBR when compared to their last prior regimens. > Additional follow-up is required to assess long-term outcomes, including progression-free survival and overall survival. 
Faculty Comments
DR VOSE: This is a single-arm, Phase II study, which combined weekly bortezomib with standard doses of bendamustine and rituximab. The patient characteristics were fairly typical of relapsed/refractory follicular lymphoma.
The waterfall plot shows that the majority of patients had an excellent response, with most having a more than 50 percent reduction in the tumors. Among the safety endpoints, the major adverse events were hematologic, and neuropathy was also reported in some patients. Overall, the regimen was fairly well tolerated by most patients.
I believe this is an active combination that will have to be evaluated with a randomized trial to determine whether it is better than the current standard regimens. 
